This company listing is no longer active
Syneos Health Management
Management criteria checks 1/4
Syneos Health's CEO is Michelle Keefe, appointed in Apr 2022, has a tenure of 1.42 years. total yearly compensation is $8.89M, comprised of 9.7% salary and 90.3% bonuses, including company stock and options. directly owns 0.034% of the company’s shares, worth €1.45M. The average tenure of the management team and the board of directors is 2.7 years and 2.3 years respectively.
Key information
Michelle Keefe
Chief executive officer
US$8.9m
Total compensation
| CEO salary percentage | 9.7% |
| CEO tenure | 1.4yrs |
| CEO ownership | 0.03% |
| Management average tenure | 2.7yrs |
| Board average tenure | 2.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | US$71m |
| Mar 31 2023 | n/a | n/a | US$148m |
| Dec 31 2022 | US$9m | US$862k | US$266m |
| Sep 30 2022 | n/a | n/a | US$287m |
| Jun 30 2022 | n/a | n/a | US$278m |
| Mar 31 2022 | n/a | n/a | US$242m |
| Dec 31 2021 | US$2m | US$567k | US$235m |
| Sep 30 2021 | n/a | n/a | US$251m |
| Jun 30 2021 | n/a | n/a | US$236m |
| Mar 31 2021 | n/a | n/a | US$198m |
| Dec 31 2020 | US$2m | US$522k | US$193m |
| Sep 30 2020 | n/a | n/a | US$192m |
| Jun 30 2020 | n/a | n/a | US$187m |
| Mar 31 2020 | n/a | n/a | US$195m |
| Dec 31 2019 | US$2m | US$550k | US$131m |
Compensation vs Market: Michelle's total compensation ($USD8.89M) is above average for companies of similar size in the German market ($USD2.43M).
Compensation vs Earnings: Michelle's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Michelle Keefe (56 yo)
1.4yrs
Tenure
US$8,889,996
Compensation
Ms. Michelle Keefe serves as Chief Executive Officer at Syneos Health, Inc since April 29, 2022 and serves as its Director since 2022. She served as President of Medical Affairs and Commercial Solutions fo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.4yrs | US$8.89m | 0.034% € 1.5m | |
| Chief Operating Officer | 1.4yrs | US$6.04m | 0.018% € 766.9k | |
| General Counsel & Corporate Secretary | 4.8yrs | US$3.52m | 0.014% € 584.6k | |
| Chief Business Officer | 5yrs | US$2.62m | 0.011% € 475.3k | |
| Consultant | less than a year | US$3.19m | 0.039% € 1.7m | |
| Chief Financial Officer | less than a year | no data | no data | |
| Senior VP of Finance & Chief Accounting Officer | 2.7yrs | no data | 0.0029% € 123.7k | |
| President of Technology & Data Solutions | 1.4yrs | no data | no data | |
| Chief Scientific Officer | 7.5yrs | no data | no data | |
| Chief Information & Digital Officer | 2.8yrs | no data | no data | |
| Senior Vice President of Investor Relations | no data | no data | no data | |
| Global Head of Corporate Communications & Marketing | 6.1yrs | no data | no data |
2.7yrs
Average Tenure
52.5yo
Average Age
Experienced Management: 8IN's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.7yrs | US$8.89m | 0.034% € 1.5m | |
| Independent Director | 6.9yrs | US$370.77k | 0.019% € 819.7k | |
| Independent Director | less than a year | US$182.56k | 0% € 0 | |
| Independent Director | 6.9yrs | US$322.77k | 0.019% € 804.9k | |
| Independent Director | 1.7yrs | US$351.39k | 0.0034% € 142.2k | |
| Independent Chairman | 4.8yrs | US$483.27k | 0.022% € 921.0k | |
| Independent Director | 2.3yrs | US$308.52k | 0.0048% € 202.2k | |
| Independent Director | 3.8yrs | US$307.77k | 0.0096% € 403.5k | |
| Independent Director | 1.7yrs | US$369.53k | 0.0034% € 143.5k |
2.3yrs
Average Tenure
60yo
Average Age
Experienced Board: 8IN's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/09/28 19:02 |
| End of Day Share Price | 2023/09/27 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Syneos Health, Inc. is covered by 23 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Bolan | Avondale Partners |
| Eric Coldwell | Baird |
| Stewart Glickman | CFRA Equity Research |